Efficiency of human monocyte-derived suppressor cell-based treatment in graft-versus-host disease prevention while preserving graft-versus-leukemia effect.
Fiche publication
Date publication
février 2021
Journal
Oncoimmunology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BONNOTTE Bernard
Tous les auteurs :
Janikashvili N, Gérard C, Thébault M, Brazdova A, Boibessot C, Cladière C, Ciudad M, Greigert H, Ouandji S, Ghesquière T, Samson M, Audia S, Saas P, Bonnotte B
Lien Pubmed
Résumé
Immunosuppressive cell-based therapy is a recent strategy for controlling Graft--Host Disease (GvHD). Such cells ought to maintain their suppressive function in inflammatory conditions and in the presence of immunosuppressive agents currently used in allogeneic hematopoietic cell transplantation (allo-HCT). Moreover, these therapies should not diminish the benefits of allo-HCT, the Graft--Leukemia (GvL) effect. We have previously reported on a novel subset of human monocyte-derived suppressor cells (HuMoSC) as a prospective approach for controlling GvHD.Objective.
Mots clés
Human monocyte-derived suppressor cells, graft-versus-host disease, graft-versus-leukemia effect, immunosuppressive drugs, inflammation, regulatory T cells
Référence
Oncoimmunology. 2021 Feb 19;10(1):1880046